The 21-gene Oncotype DX Breast Recurrence Score® assay is a prospectively-validated tool for guiding adjuvant chemotherapy (CT) decisions in patients with hormone receptor (HR)+ human epidermal growth factor receptor 2 negative (HER2‒) early-stage breast cancer (BC)1–8. Here, ERBB2 is linked to breast carcinoma.